Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block.

Article Details

Citation

Copy to clipboard

Mittal M, Raychaudhuri SP

Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block.

Indian J Dermatol Venereol Leprol. 2010 Nov-Dec;76(6):602-8; quiz 609. doi: 10.4103/0378-6323.72445.

PubMed ID

21079302 [ View in PubMed

]

Abstract

Anti-tumor necrosis factor (anti-TNF) agents have revolutionized treatment of psoriasis and many other inflammatory diseases of autoimmune origin. They have considerable advantages over the existing immunomodulators. Anti-TNF agents are designed to target a very specific component of the immune-mediated inflammatory cascades. Thus, they have lower risks of systemic side-effects. In a brief period of 10 years, a growing number of biological therapies are entering the clinical arena while many more biologicals remain on the horizon. With time, the long-term side-effects and efficacies of these individual agents will become clearer and help to determine which ones are the most suitable for long-term care. Golimumab (a human monoclonal anti-TNF-alpha antibody) and Certolizumab (a PEGylated Fab fragment of humanized monoclonal TNF-alpha antibody) are the two latest additions to the anti-TNF regimen. Here, we are providing a brief description about these two drugs and their uses.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Golimumab	Tumor necrosis factor	Protein	Humans	Yes	Antibody	Details